Mutation characteristics of osteosarcoma: a single center study of 64 cases using next-generation sequencing.
10.3760/cma.j.cn112151-20221030-00902
- VernacularTitle:单中心64例骨肉瘤二代测序突变基因特征分析
- Author:
Da Lin GAO
1
;
Rong Fang DONG
1
;
Wei Feng LIU
2
;
Li Hua GONG
1
;
Hai Rong XU
2
;
Xiao Hui NIU
2
;
Yi DING
1
Author Information
1. Deptartment of Pathology, Beijing Jishuitan Hospital, the Fourth Medical College of Peking University, Beijing 100035, China.
2. Deptartment of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, the Fourth Medical College of Peking University, Beijing 100035, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Male;
Child;
Female;
Humans;
Adolescent;
Young Adult;
Middle Aged;
Aged;
DNA Copy Number Variations;
Osteosarcoma/pathology*;
Mutation;
DNA, Neoplasm;
High-Throughput Nucleotide Sequencing;
Bone Neoplasms/pathology*;
Nucleotides
- From:
Chinese Journal of Pathology
2023;52(4):370-375
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the distribution and characteristics of gene mutations in osteosarcoma, and to analyze the frequency and types of detectable mutations, and to identify potential targets for individualized treatment of osteosarcoma. Methods: The fresh tissue or paraffin-embedded tissue samples of 64 cases of osteosarcoma that were surgically resected or biopsied and then subject to next generation sequencing, were collected from Beijing Jishuitan Hospital, China from November 2018 to December 2021. The tumor DNA was extracted to detect the somatic and germline mutations using targeted sequencing technology. Results: Among the 64 patients, 41 were males and 23 were females. The patient age ranged from 6 to 65 years with a median age of 17 years, including 36 children (under 18 years old) and 28 adults. There were 52 cases of conventional osteosarcoma, 3 cases of telangiectatic osteosarcoma, 7 cases of secondary osteosarcoma, and 2 cases of parosteosarcoma. The detection rate of gene mutations was overall 84.4% (54/64). There were 324 variations in 180 mutated genes, including 125 genes with copy number variations, 109 single nucleotide variants, 83 insertions or deletions, and 7 gene fusions. The most common mutated genes were TP53, VEGFA, CCND3, ATRX, MYC, RB1, PTEN, GLI1, CDK4 and PTPRD. Among them, TP53 had the highest mutation rate (21/64, 32.8%), single nucleotide variant was the main mutation type (14/23, 60.9%), and 2 cases carried the TP53 germline mutation. VEGFA and CCND3 showed copy number amplification simultaneously in 7 cases. Conclusions: The high-frequency mutation of TP53 suggests that it plays an important role in the pathogenesis and development of osteosarcoma. VEGFA, CCND3 and ATRX are mutated genes in osteosarcoma and worthy of further studies. Combination of pathologic diagnosis and next generation sequencing with clinical practice can guide individualized treatment for patients with refractory, recurrent and metastatic osteosarcoma.
